Are you seeking information about NSCLC that's ROS1-positive at stage 2A?
ROS1-positive NSCLC is a specific subtype where the ROS1 gene has rearranged, causing cancer cells to grow. This mutation is typically seen in people who don't have EGFR, ALK, or KRAS mutations.
Stage 2A Details:
At stage 2A, the tumor is between Show Full Answer
Are you seeking information about NSCLC that's ROS1-positive at stage 2A?
ROS1-positive NSCLC is a specific subtype where the ROS1 gene has rearranged, causing cancer cells to grow. This mutation is typically seen in people who don't have EGFR, ALK, or KRAS mutations.
Stage 2A Details:
At stage 2A, the tumor is between 4-5 centimeters, or it may have grown into the lung membranes or main airway. The cancer hasn't spread to lymph nodes or distant organs at this stage.
Treatment Approach:
Surgery (often a lobectomy) is usually the primary treatment for stage 2A. After surgery, chemotherapy is commonly recommended to eliminate any remaining cancer cells. Immunotherapy may also be added.
About ROS1-Positive Treatment:
While ROS1-targeted therapies like crizotinib, ceritinib, entrectinib, lorlatinib, repotrectinib, and taletrectinib exist, they're typically used for more advanced stages. Your oncologist will determine if targeted therapy is appropriate for your specific situation.
Outlook:
The five-year survival rate for stage 2 NSCLC is around 35 percent, though outcomes depend on tumor size, treatment type, and how your body responds to therapy.
Discussing your ROS1-positive status with your medical team will help tailor the best treatment plan for you.
October 29, 2025